Pipeline of small molecules
Autoimmune/Inflammatory Diseases & Immune-related Cancers
DiscoveryPlatform development
Key Facts
Indication
Autoimmune/Inflammatory Diseases & Immune-related Cancers
Phase
Discovery
Status
Platform development
Company
About EydisBio
Founded in 2020 and based in Durham, North Carolina, EydisBio is a private biotech startup focused on addressing high unmet medical needs in autoimmunity and inflammation. The company's core innovation is its UPCP chemoproteomics platform, which enables the discovery of intrinsically selective kinase inhibitors, aiming to improve therapeutic outcomes and developmental success rates. Led by a founder with a successful track record of company creation and drug development, EydisBio is advancing its lead TAK1 inhibitor candidate through in vivo efficacy and pilot safety studies.
View full company profile